Cargando…

A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma

BACKGROUND: We aimed to study the clinicopathologic and immunohistochemical (IHC) (CD117, c-Myc, and p53) characteristics, and overall survival of primary and secondary breast angiosarcoma (BAS). METHODS: This was a retrospective study of BAS cases diagnosed between 1997 and 2020 at our institution....

Descripción completa

Detalles Bibliográficos
Autores principales: Abada, Evi, Jang, Hyejeong, Kim, Seongho, Ali-Fehmi, Rouba, Bandyopadhyay, Sudeshna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682221/
https://www.ncbi.nlm.nih.gov/pubmed/36288741
http://dx.doi.org/10.4132/jptm.2022.08.31
_version_ 1784834802637078528
author Abada, Evi
Jang, Hyejeong
Kim, Seongho
Ali-Fehmi, Rouba
Bandyopadhyay, Sudeshna
author_facet Abada, Evi
Jang, Hyejeong
Kim, Seongho
Ali-Fehmi, Rouba
Bandyopadhyay, Sudeshna
author_sort Abada, Evi
collection PubMed
description BACKGROUND: We aimed to study the clinicopathologic and immunohistochemical (IHC) (CD117, c-Myc, and p53) characteristics, and overall survival of primary and secondary breast angiosarcoma (BAS). METHODS: This was a retrospective study of BAS cases diagnosed between 1997 and 2020 at our institution. Hematoxylin and eosin-stained slides were reviewed for tumor morphology, margin status, and lymph node metastasis. CD117, p53, D2-40, CD31, and c-Myc IHC stains were performed on 11 viable tissue blocks. Additional clinical information was obtained from the electronic medical records. RESULTS: Seventeen patients with BAS were identified. Of these, five (29%) were primary and 12 (71%) were secondary BAS, respectively. The median age at diagnosis for primary BAS was 36 years. The median age at diagnosis for secondary BAS was 67 years. The median time to secondary BAS development following radiotherapy was 6.5 years (range, 2 to 12 years). There was no significant difference between primary and secondary BAS in several histopathologic parameters examined, including histologic grade, necrosis, mitotic count, lymph node metastasis, and positive tumor margins. There was also no difference in CD117, p53, D2-40, CD31, and c-Myc expression by IHC between primary and secondary BAS. During a median followup of 21 months, primary BAS had two (40%) reported deaths and secondary BAS had three (25%) reported deaths. However, this difference in survival between both groups was not statistically significant (hazard ratio, 0.51; 95% confidence interval, 0.09 to 3.28; p = .450). CONCLUSIONS: BAS is a rare and aggressive disease. No histologic, IHC (CD117, c-Myc, and p53), or survival differences were identified between primary and secondary BAS in this study.
format Online
Article
Text
id pubmed-9682221
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Pathologists and the Korean Society for Cytopathology
record_format MEDLINE/PubMed
spelling pubmed-96822212022-12-05 A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma Abada, Evi Jang, Hyejeong Kim, Seongho Ali-Fehmi, Rouba Bandyopadhyay, Sudeshna J Pathol Transl Med Original Article BACKGROUND: We aimed to study the clinicopathologic and immunohistochemical (IHC) (CD117, c-Myc, and p53) characteristics, and overall survival of primary and secondary breast angiosarcoma (BAS). METHODS: This was a retrospective study of BAS cases diagnosed between 1997 and 2020 at our institution. Hematoxylin and eosin-stained slides were reviewed for tumor morphology, margin status, and lymph node metastasis. CD117, p53, D2-40, CD31, and c-Myc IHC stains were performed on 11 viable tissue blocks. Additional clinical information was obtained from the electronic medical records. RESULTS: Seventeen patients with BAS were identified. Of these, five (29%) were primary and 12 (71%) were secondary BAS, respectively. The median age at diagnosis for primary BAS was 36 years. The median age at diagnosis for secondary BAS was 67 years. The median time to secondary BAS development following radiotherapy was 6.5 years (range, 2 to 12 years). There was no significant difference between primary and secondary BAS in several histopathologic parameters examined, including histologic grade, necrosis, mitotic count, lymph node metastasis, and positive tumor margins. There was also no difference in CD117, p53, D2-40, CD31, and c-Myc expression by IHC between primary and secondary BAS. During a median followup of 21 months, primary BAS had two (40%) reported deaths and secondary BAS had three (25%) reported deaths. However, this difference in survival between both groups was not statistically significant (hazard ratio, 0.51; 95% confidence interval, 0.09 to 3.28; p = .450). CONCLUSIONS: BAS is a rare and aggressive disease. No histologic, IHC (CD117, c-Myc, and p53), or survival differences were identified between primary and secondary BAS in this study. The Korean Society of Pathologists and the Korean Society for Cytopathology 2022-11 2022-10-27 /pmc/articles/PMC9682221/ /pubmed/36288741 http://dx.doi.org/10.4132/jptm.2022.08.31 Text en © 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Abada, Evi
Jang, Hyejeong
Kim, Seongho
Ali-Fehmi, Rouba
Bandyopadhyay, Sudeshna
A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma
title A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma
title_full A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma
title_fullStr A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma
title_full_unstemmed A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma
title_short A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma
title_sort clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682221/
https://www.ncbi.nlm.nih.gov/pubmed/36288741
http://dx.doi.org/10.4132/jptm.2022.08.31
work_keys_str_mv AT abadaevi aclinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT janghyejeong aclinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT kimseongho aclinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT alifehmirouba aclinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT bandyopadhyaysudeshna aclinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT abadaevi clinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT janghyejeong clinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT kimseongho clinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT alifehmirouba clinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma
AT bandyopadhyaysudeshna clinicopathologicandimmunohistochemicalstudyofprimaryandsecondarybreastangiosarcoma